Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecallantide for acute HAE attacks in prepubertal children
NCT01253382Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Jun 2012
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of ecallantide in hereditary angioedema (HAE), sponsored by Takeda. Planned start Jun 2012; status: withdrawn.
02
Drugs
ecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT01253382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253382.